Press Release January 13, 2021

Atalanta Therapeutics Launches With $110 Million To Pioneer RNAi Therapeutics For Neurodegenerative Diseases

The Life Sciences team advised Atalanta Therapeutics on its launch and strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group. The total committed funding at launch with the upfront payments from the two partnerships and Series A financing is $110 million.

Atalanta is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing its proprietary RNA interference platform.

As part of the strategic collaboration with Biogen, Atalanta will develop RNAi therapeutics for multiple targets, including HTT for the treatment of Huntington’s disease, as well as additional unnamed CNS targets. Atalanta will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products.

The strategic collaboration with Genentech entails the development of RNAi therapeutics for multiple CNS targets for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease. Atalanta will be eligible to receive development and milestone payments on these programs as well as royalty payments on any resulting products.

The Goodwin team on the Biogen collaboration was led by Chris Denn and included Melissa Paddock, Amanda White, Paul Jin, Kara Kuritz, and Robert Young.

The Goodwin team on the Genentech collaboration was led by Chris Denn and included Melissa Paddock, Amanda White, and Tina Zakhary.

The Goodwin corporate team advising Atalanta is led by Michael Bison and includes Catherine Magazu, Carly Ward, and Amanda White.

For more details, read the press release and articles in Fierce Biotech, Pharma Phorum, and Seeking Alpha.